Sylvia Tobé is a biotech industry professional with more than 10 years of experience across venture investing, company creation, and translational science. Prior to joining the T1D Fund, she was a Principal at Omega Funds, where she focused on early-stage investments and company formation across various therapeutic areas including neurology, immunology, and rare diseases. She currently serves on the Boards of DiogenX, ZagBio and Islex Therapeutics and has held Board observer roles at various biotech companies including Zucara Therapeutics, Vanqua Bio, Rectify Pharma and others.

Before Omega, Sylvia spent nearly seven years at Ra Pharmaceuticals, a peptide drug discovery company focused on complement-driven rare diseases. At Ra, she contributed to the development of the company’s discovery platform and helped build preclinical and translational models supporting first-in-human studies for its lead program, Zilucoplan, now approved in multiple countries for generalized myasthenia gravis (gMG). She also provided scientific leadership across multiple internal and partnered discovery programs, including a collaboration with Merk.

Sylvia earned her Ph.D. in Biochemistry (Summa Cum Laude) from Pierre and Marie Curie University in Paris while serving as a full-time visiting fellow in the Department of Genetics at Harvard University, where she worked in synthetic biology. She also holds an M.S. from Pierre and Marie Curie University and a B.S. in Biochemistry from Joseph Fourier University in Grenoble.

Brady Bohrmann is a venture investor and operating executive with more than 30 years of experience investing in and building innovative information technology and biotechnology companies. He is currently a Managing Director at Avalon Ventures, where he focuses on early-stage information technology investments, and previously co-founded Masthead Venture Partners. Earlier in his career, he served as President and COO of Watson Technologies and as CFO of Alpha-Beta Technology, bringing both operational and financial leadership to growth-stage companies. He became involved with Breakthrough T1D (formerly JDRF) and the T1D Fund after his son, Alden, was diagnosed with type 1 diabetes in 2013, a connection that informs his ongoing commitment to the mission. He holds a B.S. in Finance from Babson College. He serves as a member of the T1D Fund’s Investment Committee.